LyondellBasell Industries: Margin Normalization And Cost Leadership Suggest Upside Potential

Moretus Research initiates coverage of LyondellBasell Industries N.V. (LYB) with a Strong Buy rating and a $78 price target, representing a 39% upside based on a 5.9x forward EV/EBITDA multiple. The firm projects LYB will generate $4.1 billion and $4.25 billion in EBITDA for FY25E and FY26E, respectively, exceeding consensus estimates, driven by cost savings and margin normalization. Key risks include prolonged global overcapacity, a slow recovery in Chinese demand, and new trade barriers.

Analysis

Moretus Research has initiated coverage on LyondellBasell Industries N.V. (LYB) with a "Strong Buy" rating and a $78 price target, signaling a potential 39% upside from current levels. This valuation is predicated on a conservative 5.9x forward EV/EBITDA multiple applied to Moretus Research's proprietary EBITDA estimates, which project $4.1 billion for FY2025 and $4.25 billion for FY2026, figures notably above current Street consensus. The bullish thesis is primarily underpinned by expectations of rapid execution on cost-saving initiatives and an anticipated, yet currently underappreciated, normalization of profit margins within the chemicals and polymers sector, where LYB holds significant exposure to polyethylene (PE), polypropylene (PP), and value-added derivatives. Despite this positive outlook, identified risks include the potential for prolonged global overcapacity, a slower-than-anticipated recovery in Chinese demand, and the emergence of new trade barriers that could negatively impact margins and delay the realization of earnings upside. Moretus Research suggests current valuation levels offer an attractive entry point for patient investors, anticipating that catalysts related to cost optimization and margin normalization could drive sizable outperformance relative to industry peers.

Key Decisions for Investors

• Investors with a longer-term horizon may consider initiating or increasing exposure to LyondellBasell Industries (LYB), given the 39% upside potential to the $78 price target, driven by anticipated above-consensus earnings and margin recovery.
• Closely monitor LYB's execution on its cost-saving programs and broader chemical sector margin trends, while also tracking key macroeconomic risk factors such as global production capacity, Chinese demand dynamics, and international trade policies.
• Assess LYB as a candidate for portfolios seeking companies with mispriced cash flow potential undergoing structural improvements, particularly if comfortable with the cyclical nature of the chemicals industry and the specified risk factors highlighted by the research.